Compounding the problem is the fact that insurance companies are reluctant to cover these anti-obesity medications, since theyre considered by many to be vanity drugs, even though overwhelming evidence suggests obesity is linked directly to multiple comorbidities
Fill out the form below, and discover the Serve You Rx difference.
A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences
We can see very clearly that this is specific to medications that are working through GLP-1 receptor pharmacology. In two other clinical trials, funded by pharmaceutical companies, which were not included in the meta-analysis due to methodological differences, the drug responses were similar between carriers and non-carriers
Until a couple months ago, these medications were only available as injectables, which discouraged some patients
These symptoms often improve over time with continued use in most patients, and NPs can reduce discontinuation by starting at a low dose and titrating gradually
